Roy S. Herbst, MD, PhD of Yale Cancer Center discusses lung cancer EGFR antibodies and where the research is going. His says that immunotherapy is all the rage these days, which is only working on about 20% of the patients. And, as a single-angle frontline, it is only using 50% or more PD-L1 positivity. Depending on the data that will emerge next year or so, EGFR antibodies might have a role, especially on the squamous FISH+ patients. So, clinicians could see the fact that there is another drug that can be used with chemotherapy and hopefully help patients with lung cancer, as well.
Lung Cancer EGFR Antibodies Where is the research going?
